A Phase 1, Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs NKTR 214 (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms EXCEL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 20 Sep 2017 According to a Nektar Therapeutics media release, the company will present data from this study at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2017.
    • 05 Jun 2017 Results published in a Nektar Therapeutics media release.
    • 02 Jun 2017 Results (n=26) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top